BUZZ-Janux 因与百时美施贵宝达成全球抗癌药物交易而股价上涨

路透中文
Jan 22
BUZZ-Janux 因与百时美<a href="https://laohu8.com/S/BMY">施贵宝</a>达成全球抗癌药物交易而股价上涨

1月22日 - ** 药物开发商Janux Therapeutics JANX.O股价盘前上涨17.33%至15.57美元

** 该公司称 (link) 它与百时美施贵宝BMY.N签署了一项全球许可协议,以开发一种新的实体瘤抗癌药物

** 该公司表示,它可能会获得高达5000万美元的预付款和近期的里程碑,另外还有高达8亿美元与进展和销售额挂钩。

** 该公司表示,如果药物获得批准并销售出去,公司将获得特许权使用费

** 该药物针对的是一种在多种癌症中都能见到的蛋白质;公司称

** 在 BMY 接手开发和全球销售之前,JANX 将负责早期研究

** 2025 年股价下跌约 74%

(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10